Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Moderna, Inc. (NASDAQ:MRNA) stock is trending on Friday. The company announced that the European Medicines Agency’s Committee for Medicinal P...
On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recomm...
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend wh...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 44.13% on an annualized basis producing an average annual return of 57.4...
Novavax (NASDAQ: NVAX) submitted an application to the FDA, seeking to amend its Emergency Use Authorization (EUA) and update its protein-based COV...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its ...
Microsoft Corp (NASDAQ:MSFT) backed OpenAI, in partnership with startup Color Health, has unveiled a new initiative to harness artificial intellige...
Moderna, Inc. (NASDAQ: MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, tar...
On CNBC's “Halftime Report Final Trades,” Liz Young of SoFi named The Energy Select Sector SPDR Fund (NYSE:XLE) as her final trade...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...